Day: December 5, 2021

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

First and only neutralizing antibody therapy for this age group SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”) has expanded the emergency use authorization (“EUA”) for etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555) administered together (the “Therapy”) to include certain high-risk pediatric patients from birth to under 12 years old for the treatment of mild to moderate COVID-19 as well as post-exposure prophylaxis, according to Eli Lilly and Company (“Lilly”), the company’s global partner. The Therapy has been the first and only authorized neutralizing antibody...

Continue reading

Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron

Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron

A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity. Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients infected with existing and emerging SARS-CoV-2 variants of concern, including Omicron. A promising candidate of the series with unique features distinguished from SARS-CoV-2 MPro inhibitors published by others has been systematically evaluated and advanced to late stage of pre-clinical phase. SAN DIEGO, Dec. 05, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for...

Continue reading

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate

Bavarian Nordic’s non-adjuvanted COVID-19 vaccine candidate, ABNCoV2 (100μg), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodies The large boosting effect of ABNCoV2 elevated the neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21 A similar fold increase was observed for all SARS-CoV-2 variants tested (Wuhan, Alpha, Beta and Delta) following the booster vaccination with ABNCoV2 The vaccine was well-tolerated, with no serious adverse events reported These initial results confirm the potential of ABNCoV2 to function as a universal COVID-19 booster vaccine The Company’s management will host a conference call tomorrow at 2 pm CET (8 am EST) to discuss the results COPENHAGEN,...

Continue reading

With Offices on Four Continents, US Capital Global Champions Diversity and Inclusion

San Francisco, California, USA., November 30, 2021 – Following its rapid expansion over the past 24 months, US Capital Global now operates from 13 offices in 10 countries. The group’s global presence allows it to provide the best customized financial and investment solutions for its clients, often by breaking through international barriers that have traditionally hampered the industry. The upshot of this expansion across four continents is, of course, increased diversity in its investment officers, support staff, clients, and partners. As a global group serving global clients, US Capital Global prides itself on its diversity. Each of its office locations is driven by a strong team sharing different ethnicities, nationalities, genders, religions, education, and political outlooks, and yet united by a deep-rooted company culture of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.